Dual inhibition of glycolysis and glutaminolysis as a therapeutic strategy in the treatment of ovarian cancer

Cancer cell metabolism is required to support the biosynthetic demands of cell growth and cell division, and to maintain reduction oxidaton (redox) homeostasis. This study was designed to test the effects of glucose and glutamine on ovarian cancer cell growth and explore the inter-relationship between glycolysis and glutaminolysis. The SKOV3, IGROV-1 and Hey ovarian cancer cell lines were assayed for glucose, pyruvate and glutamine dependence by analyzing cytotoxicity, cell cycle progression, apoptosis and ATP production. As determined by MTT assay, glucose stimulated cell growth while the combination of glucose, glutamine and pyruvate resulted in the greatest stimulation of cell proliferation. Furthermore, 2-deoxy-glucose (2-DG) and 3-bromopyruvate (3-BP) induced apoptosis, caused G1 phase cell cycle arrest and reduced glycolytic activity. Moreover, 2-DG in combination with a low dose of aminooxyacetate (AOA) synergistically increased the sensitivity to 2-DG in the inhibition of cell growth in the ovarian cancer cell lines. These studies suggest that dual inhibition of glycolysis and glutaminolysis may be a promising therapeutic strategy for the treatment of ovarian cancer.

• Publication year

  2017

• Venue

  OncoTarget

• Publication date

  2017-06-29

• Fields of study

  Medicine

• Identifiers
  DOI 10.18632/oncotarget.18854PMID 28733531PMCID 5609942
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Chemotherapy for epithelial ovarian, fallopian tube and primary peritoneal cancer.

  2017cited by this paper
• The Application and Outcome of Standard of Care Treatment in Elderly Women with Ovarian Cancer: A Literature Review over the Last 10 Years

  2016cited by this paper
• NAMPT suppresses glucose deprivation-induced oxidative stress by increasing NADPH levels in breast cancer

  2016cited by this paper
• The HK2 Dependent “Warburg Effect” and Mitochondrial Oxidative Phosphorylation in Cancer: Targets for Effective Therapy with 3-Bromopyruvate

  2016cited by this paper
• Warburg Effect - a Consequence or the Cause of Carcinogenesis?

  2016cited by this paper
• Novel mechanisms and approaches to overcome multidrug resistance in the treatment of ovarian cancer.

  2016cited by this paper
• Glutaminase inhibitor compound 968 inhibits cell proliferation and sensitizes paclitaxel in ovarian cancer.

  2016cited by this paper
• NT1014, a novel biguanide, inhibits ovarian cancer growth in vitro and in vivo

  2016cited by this paper
• Resveratrol inhibits ovarian tumor growth in an in vivo mouse model

  2016cited by this paper
• Erratum to: Rectocutaneous fistula with transmigration of the suture: a rare delayed complication of vault fixation with the sacrospinous ligament

  2016cited by this paper
• A comparative analysis of inhibitors of the glycolysis pathway in breast and ovarian cancer cell line models

  2015cited by this paper
• Glutamine promotes ovarian cancer cell proliferation through the mTOR/S6 pathway

  2015cited by this paper
• Targeting Glutamine Metabolism in Breast Cancer with Aminooxyacetate

  2015cited by this paper
• Glucose promotes cell proliferation, glucose uptake and invasion in endometrial cancer cells via AMPK/mTOR/S6 and MAPK signaling.

  2015influential reference
• Quantitative metabolic parameters measured on F-18 FDG PET/CT predict survival after relapse in patients with relapsed epithelial ovarian cancer.

  2015cited by this paper
• Molecular mechanisms of cell death: central implication of ATP synthase in mitochondrial permeability transition

  2014cited by this paper
• Ovarian tumor-initiating cells display a flexible metabolism.

  2014cited by this paper
• Targeting glucose metabolism in patients with cancer

  2014influential reference
• 2-Deoxy-D-glucose targeting of glucose metabolism in cancer cells as a potential therapy.

  2014cited by this paper
• D-Glucose-Induced Cytotoxic, Genotoxic, and Apoptotic Effects on Human Breast Adenocarcinoma (MCF-7) Cells

  2014cited by this paper
• Glucose restriction decreases telomerase activity and enhances its inhibitor response on breast cancer cells: possible extra-telomerase role of BIBR 1532

  2014cited by this paper
• Glucose Deprivation Induces G2/M Transition-Arrest and Cell Death in N-GlcNAc2-Modified Protein-Producing Renal Carcinoma Cells

  2014cited by this paper
• Re-thinking cell cycle regulators: the cross-talk with metabolism

  2013cited by this paper
• Glucose Starvation Induces Apoptosis in a Model of Acute T Leukemia Dependent on Caspase-3 and Apoptosis-Inducing Factor: A Therapeutic Strategy

  2013cited by this paper
• Study of Global Transcriptional Changes of N-GlcNAc2 Proteins-Producing T24 Bladder Carcinoma Cells under Glucose Deprivation

  2013cited by this paper
• Cancer cell metabolism: implications for therapeutic targets

  2013cited by this paper
• Starving Tumors: Inhibition of Glycolysis Reduces Viability of Human Endometrial and Ovarian Cancer Cells and Enhances Antitumor Efficacy of GnRH Receptor-Targeted Therapies

  2013cited by this paper
• Metabolic changes during ovarian cancer progression as targets for sphingosine treatment.

  2013cited by this paper
• Tumor glycolysis as a target for cancer therapy: progress and prospects

  2013influential reference
• Glycolysis Inhibition Sensitizes Non–Small Cell Lung Cancer with T790M Mutation to Irreversible EGFR Inhibitors via Translational Suppression of Mcl-1 by AMPK Activation

  2013cited by this paper
• 3-bromopyruvate: Targets and outcomes

  2012cited by this paper
• Central role of lactic acidosis in cancer cell resistance to glucose deprivation‐induced cell death

  2012cited by this paper
• The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type.

  2012cited by this paper
• Glucose deprivation activates AMPK and induces cell death through modulation of Akt in ovarian cancer cells.

  2011cited by this paper
• Dual Inhibition of Tumor Energy Pathway by 2-Deoxyglucose and Metformin Is Effective against a Broad Spectrum of Preclinical Cancer Models

  2011cited by this paper
• Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia

  2011cited by this paper
• Cancer Testis Antigens: Novel Biomarkers and Targetable Proteins for Ovarian Cancer

  2011cited by this paper
• The impact of diabetes on survival in women with ovarian cancer.

  2011cited by this paper
• Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells.

  2010influential reference
• Risk of Cancer Following Hospitalization for Type 2 Diabetes

  2010cited by this paper
• AMP kinase signaling determines whether c-Jun N-terminal kinase promotes survival or apoptosis during glucose deprivation.

  2009cited by this paper
• Glucose deprivation-induced metabolic oxidative stress and cancer therapy.

  2009cited by this paper
• Cancer cell metabolism: Warburg and beyond.

  2008cited by this paper
• The biology of cancer: metabolic reprogramming fuels cell growth and proliferation.

  2008cited by this paper
• Cancer statistics

  1989cited by this paper

• Metabolic Reprogramming Shapes the Progression and Therapeutic Landscape of Ovarian Cancer

  2025cites this paper
• Local glycolysis-modulating hydrogel microspheres for a combined anti-tumor and anti-metastasis strategy through metabolic trapping strategy.

  2024cites this paper
• Effect of differential deprivation of nutrients on cellular proliferation, oxidative stress, mitochondrial function, and cell migration in MDA-MB-231, HepG2, and HeLa cells

  2023cites this paper
• The Role of Reprogrammed Glucose Metabolism in Cancer

  2023cites this paper
• Dietary approaches for exploiting metabolic vulnerabilities in cancer.

  2023cites this paper
• 2-Deoxy-D-glucose increases the sensitivity of glioblastoma cells to BCNU through the regulation of glycolysis, ROS and ERS pathways: in vitro and in vivo validation.

  2022cites this paper
• Diaminobutoxy-substituted Isoflavonoid (DBI-1) Enhances the Therapeutic Efficacy of GLUT1 inhibitor BAY-876 by Modulating Metabolic Pathways in Colon Cancer Cells.

  2022cites this paper
• Insulin and cancer: a tangled web

  2022cites this paper
• Diffusion‐induced anisotropic cancer invasion: a novel experimental method based on tumour spheroids

  2022cites this paper
• Novel mutation in hexokinase 2 confers resistance to 2-deoxyglucose by altering protein dynamics

  2022cites this paper
• Upregulation of Succinate Dehydrogenase (SDHA) Contributes to Enhanced Bioenergetics of Ovarian Cancer Cells and Higher Sensitivity to Anti-Metabolic Agent Shikonin

  2022cites this paper
• Efficacy evaluation of multi-immunotherapy in ovarian cancer: From bench to bed

  2022cites this paper
• Photochemical Targeting of Mitochondria to Overcome Chemoresistance in Ovarian Cancer †

  2022cites this paper
• Emerging roles of cystathionine β-synthase in various forms of cancer

  2022cites this paper
• Recent advancements in therapeutic targeting of the Warburg effect in refractory ovarian cancer: A promise towards disease remission.

  2021cites this paper
• Targeting the tumour microenvironment in platinum-resistant ovarian cancer.

  2021cites this paper
• Investigation of glucose catabolism in hypoxic Mcf 7 breast cancer culture

  2021cites this paper
• Hyperosmolarity Triggers the Warburg Effect in Chinese Hamster Ovary Cells and Reveals a Reduced Mitochondria Horsepower

  2021cites this paper
• Development of a Rapid In Vitro Screening Assay Using Metabolic Inhibitors to Detect Highly Selective Anticancer Agents

  2021cites this paper
• Recent advances in the role of Th17/Treg cells in tumor immunity and tumor therapy

  2021cites this paper
• Glucose Transporters as a Target for Anticancer Therapy

  2021cites this paper
• Co-delivery of 2-Deoxyglucose and a Glutamine Metabolism Inhibitor V9302 via a Prodrug Micellar Formulation for Synergistic Targeting of Metabolism in Cancer.

  2020cites this paper
• p53-dependent glutamine usage determines susceptibility to oxidative stress in radioresistant head and neck cancer cells.

  2020cites this paper
• Power of two: Combination of therapeutic approaches involving glucose transporter (GLUT) inhibitors to combat cancer.

  2020cites this paper
• Analysis of differential metabolites in lung cancer patients based on metabolomics and bioinformatics.

  2020cites this paper
• Potential Applications of NRF2 Modulators in Cancer Therapy

  2020cites this paper
• Unlocking the potential of HK2 in cancer metabolism and therapeutics.

  2020cites this paper
• Co-Delivery of 2-Dg and V9302 Via a Prodrug Micellar Formulation for Synergistic Targeting of Metabolism in Cancer

  2019cites this paper
• MicroRNA targeting energy metabolism in ovarian cancer: a potent contender for future therapeutics.

  2019cites this paper
• Overcoming radioresistance in WiDr cells with heavy ion irradiation and radiosensitization by 2-deoxyglucose with photon irradiation

  2019cites this paper
• Inhibition of Glucose Transporters and Glutaminase Synergistically Impairs Tumor Cell Growth.

  2019cites this paper
• Efficacy of Dual Inhibition of Glycolysis and Glutaminolysis for Therapy of Renal Lesions in Tsc2+/− Mice

  2019cites this paper
• Mitochondrial membrane depolarization enhances TRAIL-induced cell death in adult human granulosa tumor cells, KGN, through inhibition of BIRC5

  2018cites this paper
• Biological and metabolic effects of IACS-010759, an OxPhos inhibitor, on chronic lymphocytic leukemia cells

  2018cites this paper
• Tumor metabolism regulating chemosensitivity in ovarian cancer

  2018cites this paper
• Antitumor action of 3‐bromopyruvate implicates reorganized tumor growth regulatory components of tumor milieu, cell cycle arrest and induction of mitochondria‐dependent tumor cell death

  2018cites this paper
• A novel small-molecule arylsulfonamide causes energetic stress and suppresses breast and lung tumor growth and metastasis

  2017influential citation
• Reversal of obesity-driven aggressiveness of endometrial cancer by metformin.

  2017cites this paper